ReviewTherapeutic advances in musculoskeletal disease2017
Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential.
Review in Therapeutic advances in musculoskeletal disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis.Clinical rheumatology · 2020Pooled it
- Osteoporosis and Alzheimer's Disease: The Role of Sclerostin.Current osteoporosis reports · 2026Review
- Romosozumab Achieves Consistent Lumbar Spine BMD Gains Across All BMI Categories: The Apparent Enhanced Response in Underweight Patients is a Mathematical Artifact of Percentage Change.Calcified tissue international · 2026Article
- Sclerostin in Vascular Calcification: Hypoxia-Driven Regulation and Therapeutic Modulation by Natural Products.Current atherosclerosis reports · 2026Review
- Mathematical modeling of bone remodeling after surgical menopause.Frontiers in systems biology · 2026Article
- Integrative Epigenomic and Targeted Protein Analysis in MRONJ: Correlating DNA Methylation with Bone Biomarkers.International journal of molecular sciences · 2025Article
- Review
- Signaling Pathways Driving MSC Osteogenesis: Mechanisms, Regulation, and Translational Applications.International journal of molecular sciences · 2025Review
- Overexpression of miR17 ~ 92 in Myeloid Cells in Mice Increased Bone Mass Through Reduced Bone Resorption and Increased Bone Formation in Sex-Dependent Manner.Calcified tissue international · 2025Article
- Pilot study of the effect of surgical menopause on bone mineral density and quality in patients with gynecological malignancies.The journal of obstetrics and gynaecology research · 2025Article
- Chemotherapy-induced osteoporosis in pediatric oncology: pathophysiology and treatment.Pediatric endocrinology, diabetes, and metabolism · 2025Review
- Serum proteome profiling of plateau acclimatization in men using Olink proteomics approach.Physiological reports · 2024Article
- Altered extracellular matrix and mechanotransduction gene expression in rat bone tissue following long-term estrogen deficiency.JBMR plus · 2024Article
- Immune microenvironment: novel perspectives on bone regeneration disorder in osteoradionecrosis of the jaws.Cell and tissue research · 2023Review
- Anti-sclerostin antibodies: a new frontier in fragility fractures treatment.Therapeutic advances in musculoskeletal disease · 2023Review
- The clinician's guide to prevention and treatment of osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2022Article
- Osteoporosis Prevention and Treatment: The Risk of Comorbid Cardiovascular Events in Postmenopausal Women.Cureus · 2022Review
- Over-Representation of Recessive Osteogenesis Imperfecta in Asian Indian Children.Journal of pediatric genetics · 2022Article
- Osteocytes and Estrogen Deficiency.Current osteoporosis reports · 2021Review
- Activation of Wnt signalling reduces the population of cancer stem cells in ameloblastoma.Cell proliferation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sclerostin is an osteocyte-derived glycoprotein that inhibits Wnt/β-catenin signaling and activation of osteoblast function, thereby inhibiting bone formation. It plays a vital role in the regulation of skeletal growth. In adults, sclerostin secretion is modulated by skeletal loading (increased secretion with immobilization; less with weight bearing) and by hormonal/cytokine actions on the osteocyte. Sclerostin deficiency syndromes in humans and animals are characterized by high bone mass of normal quality. In animal models of osteoporosis, inhibition of sclerostin by monoclonal antibodies induces osteoblast activity and new bone formation, normalizing bone mass and improving bone architecture and strength. In recently completed clinical trials, anti-sclerostin antibody therapy results in marked increases in bone mineral density and rapid and substantial reduction in fracture risk. This review will focus on these recent studies and anticipate the role of anti-sclerostin therapy in the management of patients with osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.